JP2004534503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004534503A5 JP2004534503A5 JP2002535697A JP2002535697A JP2004534503A5 JP 2004534503 A5 JP2004534503 A5 JP 2004534503A5 JP 2002535697 A JP2002535697 A JP 2002535697A JP 2002535697 A JP2002535697 A JP 2002535697A JP 2004534503 A5 JP2004534503 A5 JP 2004534503A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- amino acid
- group
- substitution selected
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000006467 substitution reaction Methods 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 9
- 230000004988 N-glycosylation Effects 0.000 description 7
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 6
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 3
- 102000055691 human APC Human genes 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 101500025568 Homo sapiens Saposin-D Proteins 0.000 description 2
- 208000010378 Pulmonary Embolism Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010047249 Venous thrombosis Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229940100689 human protein c Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24226800P | 2000-10-18 | 2000-10-18 | |
| DKPA200001560 | 2000-10-18 | ||
| US30015401P | 2001-06-21 | 2001-06-21 | |
| DKPA200100970 | 2001-06-21 | ||
| PCT/DK2001/000679 WO2002032461A2 (en) | 2000-10-18 | 2001-10-15 | Protein c or activated protein c-like molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004534503A JP2004534503A (ja) | 2004-11-18 |
| JP2004534503A5 true JP2004534503A5 (enExample) | 2006-01-05 |
| JP4071105B2 JP4071105B2 (ja) | 2008-04-02 |
Family
ID=27439828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002535697A Expired - Fee Related JP4071105B2 (ja) | 2000-10-18 | 2001-10-15 | プロテインｃまたは活性化プロテインｃ様分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030027299A1 (enExample) |
| EP (1) | EP1328622A2 (enExample) |
| JP (1) | JP4071105B2 (enExample) |
| KR (1) | KR20030060915A (enExample) |
| AU (2) | AU1038802A (enExample) |
| CA (1) | CA2425221A1 (enExample) |
| MX (1) | MXPA03003388A (enExample) |
| WO (1) | WO2002032461A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003106666A2 (en) * | 2002-06-14 | 2003-12-24 | Maxygen Aps | Protein c variants with altered properties |
| WO2004044190A2 (en) * | 2002-11-11 | 2004-05-27 | Maxygen Aps | Zymogen-like protein c polypeptides |
| WO2004113385A1 (en) * | 2003-06-20 | 2004-12-29 | Maxygen Holdings Ltd. | Protein c propeptide variants |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| WO2005007820A2 (en) * | 2003-07-08 | 2005-01-27 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| WO2005042011A1 (en) * | 2003-11-04 | 2005-05-12 | Novo Nordisk A/S | Pharmaceutical composition comprising a protein c polypeptide and a blood glucose regulator |
| JP4707327B2 (ja) * | 2004-01-27 | 2011-06-22 | 旭化成ファーマ株式会社 | ポリペプタイド類の吸着防止剤 |
| WO2006044294A2 (en) * | 2004-10-14 | 2006-04-27 | Eli Lilly And Company | Human protein c analogs |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| WO2007115724A2 (en) * | 2006-04-11 | 2007-10-18 | Csl Behring Gmbh | Method of increasing the in vivo recovery of therapeutic polypeptides |
| EP2097096B1 (en) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| EP2242875A4 (en) * | 2008-01-15 | 2012-04-04 | Univ British Columbia | PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND |
| EP2103310A1 (en) * | 2008-03-19 | 2009-09-23 | Universiteit Maastricht | Method for the prevention or treatment of ischemia reperfusion injury. |
| WO2009130198A2 (en) | 2008-04-21 | 2009-10-29 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| WO2010062756A2 (en) * | 2008-11-03 | 2010-06-03 | University Of Rochester | Preventing and treating sepsis |
| WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
| ES2676422T3 (es) | 2012-07-04 | 2018-07-19 | Zz Biotech Llc | Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel |
| US20170042982A1 (en) * | 2014-04-16 | 2017-02-16 | Zz Biotech Llc | Treatment of abnormal cutaneous scarring |
| CN106488773B (zh) | 2014-04-16 | 2020-02-11 | Zz生物技术有限责任公司 | Apc类似物用于创伤愈合的用途 |
| KR101893403B1 (ko) * | 2017-03-17 | 2018-08-30 | 주식회사 유비프로틴 | 단백질 반감기를 증가시키는 방법 |
| KR101955884B1 (ko) * | 2017-03-17 | 2019-03-08 | 주식회사 유비프로틴 | 단백질 반감기를 증가시키는 방법 |
| KR101889743B1 (ko) * | 2017-03-17 | 2018-08-20 | 주식회사 유비프로틴 | 단백질 반감기를 증가시키는 방법 |
| KR101955886B1 (ko) * | 2017-05-05 | 2019-03-12 | 주식회사 유비프로틴 | 안지오포이에틴-1 반감기를 증가시키는 방법 |
| KR101947342B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | Gm-csf 반감기를 증가시키는 방법 |
| KR101955885B1 (ko) * | 2017-05-05 | 2019-03-08 | 주식회사 유비프로틴 | Pdgfa 반감기를 증가시키는 방법 |
| KR101947339B1 (ko) * | 2017-05-05 | 2019-02-12 | 주식회사 유비프로틴 | Pdgfb 반감기를 증가시키는 방법 |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270040A (en) * | 1985-02-08 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US4959318A (en) * | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| US4968626A (en) * | 1985-08-15 | 1990-11-06 | Board Of Reagents Of The University Of Washington | DNA sequence coding for protein C |
| US5516650A (en) * | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5196322A (en) * | 1987-12-28 | 1993-03-23 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
| US5648254A (en) * | 1988-01-15 | 1997-07-15 | Zymogenetics, Inc. | Co-expression in eukaryotic cells |
| US5041376A (en) * | 1988-12-09 | 1991-08-20 | The Board Of Regents Of The University Of Texas System | Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins |
| JP2774154B2 (ja) * | 1989-08-10 | 1998-07-09 | 帝人株式会社 | 活性化ヒトプロテインｃ誘導体 |
| US5225537A (en) * | 1989-12-29 | 1993-07-06 | Zymogenetics, Inc. | Methods for producing hybrid phospholipid-binding proteins |
| ES2113878T3 (es) * | 1989-12-29 | 1998-05-16 | Zymogenetics Inc | Proteina c hibrida. |
| US5358932A (en) * | 1989-12-29 | 1994-10-25 | Zymogenetics, Inc. | Hybrid protein C |
| IL97311A0 (en) * | 1990-02-23 | 1992-05-25 | Lilly Co Eli | Vectors and compounds for expression of glycosylation mutants of human protein c |
| US5270178A (en) * | 1990-02-23 | 1993-12-14 | Eli Lilly And Company | Vectors and compounds for expression of zymogen forms of human protein C |
| MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| JPH0892294A (ja) * | 1994-09-29 | 1996-04-09 | Teijin Ltd | ヒト活性化プロテインｃ誘導体 |
| WO1998020118A1 (en) * | 1996-11-08 | 1998-05-14 | Oklahoma Medical Research Foundation | Modified protein c and methods of use thereof |
| US5837843A (en) * | 1996-11-08 | 1998-11-17 | Oklahoma Medical Research Foundation | Modified protein C |
| IL140326A0 (en) * | 1999-04-30 | 2002-02-10 | Lilly Co Eli | Protein c derivatives |
| EP1263943A1 (en) * | 2000-02-11 | 2002-12-11 | Eli Lilly & Company | Protein c derivatives |
-
2001
- 2001-10-15 EP EP01978215A patent/EP1328622A2/en not_active Withdrawn
- 2001-10-15 WO PCT/DK2001/000679 patent/WO2002032461A2/en not_active Ceased
- 2001-10-15 AU AU1038802A patent/AU1038802A/xx active Pending
- 2001-10-15 CA CA002425221A patent/CA2425221A1/en not_active Abandoned
- 2001-10-15 KR KR10-2003-7005475A patent/KR20030060915A/ko not_active Withdrawn
- 2001-10-15 MX MXPA03003388A patent/MXPA03003388A/es not_active Application Discontinuation
- 2001-10-15 JP JP2002535697A patent/JP4071105B2/ja not_active Expired - Fee Related
- 2001-10-15 AU AU2002210388A patent/AU2002210388B2/en not_active Ceased
- 2001-10-17 US US09/978,917 patent/US20030027299A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004534503A5 (enExample) | ||
| Mandl et al. | Adaptation of tick-borne encephalitis virus to BHK-21 cells results in the formation of multiple heparan sulfate binding sites in the envelope protein and attenuation in vivo | |
| Proost et al. | Truncation of macrophage-derived chemokine by CD26/dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interaction | |
| WO2001083527A3 (en) | Glucagon antagonists | |
| JPH09511652A (ja) | 減少した吸着性と増加した加水分解性を有するズブチリシンｂｐｎ′変異体 | |
| JPH09502610A (ja) | 吸着性が減少して加水分解性が増加したズブチリシンｂｐｎ′変異体 | |
| CN1894281B (zh) | 病毒感染的治疗 | |
| Maraganore | Thrombin, thrombin inhibitors, and the arterial thrombotic process | |
| CN105246503A (zh) | Pcsk9的新颖结合蛋白 | |
| JP2003517284A (ja) | 免疫応答を変調する方法及び組成物 | |
| AU709054B2 (en) | Compositions for the inhibition of TNF formation and uses thereof | |
| CA2139127A1 (en) | Compositions for the inhibition of protein hormone formation and uses thereof | |
| JP2019525764A5 (enExample) | ||
| KR102544139B1 (ko) | 피부 경화증의 치료를 위한 매트릭스 금속단백분해효소를 포함하는 자가 유래 세포의 전달 | |
| Maly et al. | How and why cells make superoxide: the" phagocytic" NADPH oxidase | |
| KR20140098713A (ko) | 혈액응고인자 ⅶ를 포함하는 조성물에서 바이러스의 불활성화 방법 | |
| Wang et al. | Cleavage of CCK 33 by Recombinant PC2in Vitro | |
| CA2078000C (en) | Neutrophil stimulating peptides | |
| CN1341120A (zh) | 骨刺激因子 | |
| US20110044999A1 (en) | Il-32 modulators | |
| JP2001269184A5 (enExample) | ||
| US5843693A (en) | Assay method for screening for inhibitors of proTNF conversion | |
| CN111072780B (zh) | 白血病干细胞抑制剂及其在治疗慢性粒细胞白血病中的应用 | |
| AU676842B2 (en) | Neutrophil stimulating peptides | |
| RU2003114432A (ru) | Молекулы на основе белка с или активированного белка с |